Merck, Inc.
Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 150
- Registration Number
- NCT03715205
- Locations
- 🇮🇳
Indraprastha Apollo Hospitals ( Site 0008), New Delhi, Delhi, India
🇮🇳All India Institute of Medical Sciences ( Site 0012), New Delhi, Delhi, India
🇮🇳Nizam's Institute of Medical Sciences ( Site 0011), Hyderabad, Andhra Pradesh, India
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 794
- Registration Number
- NCT03713593
- Locations
- 🇺🇸
Emory University Winship Cancer Institute ( Site 0639), Atlanta, Georgia, United States
🇺🇸Beth Israel Deaconess Medical Center ( Site 0716), Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital ( Site 0603), Boston, Massachusetts, United States
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
- Conditions
- High-risk Non-muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1397
- Registration Number
- NCT03711032
- Locations
- 🇯🇵
Institute of Science Tokyo Hospital ( Site 0409), Tokyo, Japan
🇺🇸Alaska Urological Institute dba Alaska Clinical Research Center ( Site 1083), Anchorage, Alaska, United States
🇺🇸Mayo Clinic in Arizona - Phoenix ( Site 1094), Phoenix, Arizona, United States
A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038)
- First Posted Date
- 2018-10-04
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 175
- Registration Number
- NCT03696108
- Locations
- 🇯🇵
Fukuoka University Chikushi Hospital ( Site 3886), Chikushino, Fukuoka, Japan
🇯🇵National Hospital Organization Nagoya Medical Center ( Site 3898), Nagoya, Aichi, Japan
🇯🇵Nagoya City University Hospital ( Site 3899), Nagoya, Aichi, Japan
A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: Prevnar 13™Biological: V114
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2409
- Registration Number
- NCT03692871
- Locations
- 🇫🇮
Tampereen yliopisto Etela-Helsingin Rokotetutkimusklinikka ( Site 0064), Helsinki, Finland
🇫🇮Seinajoki Vaccine Research Center ( Site 0070), Seinajoki, Finland
🇹🇭Chulalongkorn University ( Site 0102), Bangkok, Thailand
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
- Conditions
- Stomach Neoplasms
- Interventions
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1579
- Registration Number
- NCT03675737
- Locations
- 🇨🇷
CIMCA Centro de Investigacion y Manejo del Cancer ( Site 3001), San Jose, Costa Rica
🇨🇷Policlinico San Bosco ( Site 3002), San Jose, Costa Rica
🇨🇷ICIMED - Instituto de Investigacion en Ciencias Medicas ( Site 3000), San Jose, Costa Rica
Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)
- Conditions
- Human Immunodeficiency Virus (HIV) Infection
- Interventions
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT03667547
- Locations
- 🇯🇵
Medical Corporation Houeikai Sekino Clinical Pharmacology Clinic ( Site 0001), Tokyo, Japan
Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)
- Conditions
- Melanoma
- Interventions
- Biological: Pembrolizumab Dose CBiological: Pembrolizumab Dose DBiological: Pembrolizumab Dose ABiological: Pembrolizumab Dose B
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 138
- Registration Number
- NCT03665597
- Locations
- 🇿🇦
Cape Town Oncology Trials Pty Ltd ( Site 0028), Kraaifontein, Western Cape, South Africa
🇦🇺Royal Adelaide Hospital ( Site 0002), Adelaide, South Australia, Australia
🇿🇦WITS Clinical Research CMJAH Clinical Trial Site ( Site 0030), Johannesburg, Gauteng, South Africa
Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 118
- Registration Number
- NCT03664024
- Locations
- 🇨🇦
CISSS de la Monteregie-Centre ( Site 0801), Greenfield Park, Quebec, Canada
🇭🇺Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 0401), Szolnok, Hungary
🇮🇱Meir Medical Center ( Site 0501), Kfar-Saba, Israel
A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034)
- Conditions
- Endometriosis-related Pain
- Interventions
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 187
- Registration Number
- NCT03654326
- Locations
- 🇺🇸
Synexus US Phoenix Southeast ( Site 0729), Chandler, Arizona, United States
🇺🇸Lynn Institute of the Ozarks ( Site 0720), Little Rock, Arkansas, United States
🇺🇸Thameside OBGYN Center ( Site 0747), Groton, Connecticut, United States